Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.90
-0.13 (-2.16%)
At close: Jun 26, 2026, 4:00 PM EDT
6.01
+0.11 (1.86%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
70
Market Cap
1.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 257.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 400.00K | 346.00K | 640.74% |
| Dec 31, 2015 | 54.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 300.00K | -200.00K | -40.00% |
| Dec 31, 2008 | 500.00K | - | - |
| Dec 31, 2007 | 500.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Immunocore Holdings | 412.81M |
| Maravai LifeSciences Holdings | 204.73M |
| Ascentage Pharma Group International | 82.08M |
| Maze Therapeutics | 20.00M |
| Capricor Therapeutics | 11.13M |
SVRA News
- 16 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 20 days ago - Savara says CFO Dave Lowrance stepping down for health reasons - TheFly
- 20 days ago - Savara Announces Chief Financial and Administrative Officer Transition - Business Wire
- 24 days ago - Savara Transcript: AGM 2026 - Transcripts
- 25 days ago - Savara Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - Savara presents poster at ATS 2026 International Conference on IMPALA-2 - TheFly
- 5 weeks ago - Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 - Business Wire